, Ordre des médecins. Relation médecin

C. Bauters, Prognosis of Patients With Stable Coronary Artery Disease (from the CORONOR Study), Am J Cardiol, vol.113, pp.1142-1145, 2014.

J. J. Goldberger, R. O. Bonow, M. Cuffe, L. Liu, Y. Rosenberg et al., Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction, J Am Coll Cardiol, vol.66, issue.13, pp.1431-1472, 2015.

C. Andersson, D. Shilane, A. S. Go, T. I. Chang, D. Kazi et al., BetaBlocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease, J Am Coll Cardiol, vol.64, issue.3, pp.247-52, 2014.

S. Bangalore, G. Steg, P. Deedwania, K. Crowley, K. A. Eagle et al., ?-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease, JAMA, vol.308, issue.13, pp.1340-1349, 2012.

C. Baigent, L. Blackwell, R. Collins, J. Emberson, and J. Godwin, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Antithrombotic Trialists' (ATT) Collaboration, vol.373, pp.1849-60, 2009.

S. R. Mehta and S. Yusuf, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, Eur Heart J, vol.21, issue.24, pp.2033-2074, 2000.

L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson et al., Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

.. J. Engl and . Med, , vol.361, pp.1045-1057, 2009.

G. Montalescot, S. D. Wiviott, E. Braunwald, S. A. Murphy, C. M. Gibson et al., Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial, Lancet Lond Engl, vol.373, issue.9665, pp.723-754, 2009.

C. P. Cannon, E. Braunwald, C. H. Mccabe, D. J. Rader, J. L. Rouleau et al., Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes, N Engl J Med, vol.350, issue.15, pp.1495-504, 2004.

V. Durand and D. , Statines : des informations disponibles à la prescription courante, vol.35, pp.151-154, 2014.

, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet Lond Engl, vol.344, issue.8934, pp.1383-1392, 1994.

, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet Lond Engl, vol.360, issue.9326, pp.7-22, 2002.

. Long-term, Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, vol.339, pp.1349-57, 2019.

J. Shepherd, S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer et al., Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, N Engl J Med, vol.333, issue.20, pp.1301-1309, 1995.

B. Ibanez, S. James, S. Agewall, M. J. Antunes, C. Bucciarelli-ducci et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC), Eur Heart J, vol.00, pp.1-66, 2017.

F. M. Sacks, M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels

, N Engl J Med, vol.335, issue.14, pp.1001-1010, 1996.

, HAS. Guide du parcours de soin maladie coronarienne stable

G. R. Dagenais, J. Pogue, K. Fox, M. L. Simoons, and S. Yusuf, Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials, Lancet Lond Engl, vol.368, issue.9535, pp.581-589, 2006.

S. Yusuf, P. Sleight, J. Pogue, J. Bosch, and R. Davies, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, Heart Outcomes Prevention Evaluation Study Investigators, vol.342, pp.145-53, 200020.

, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet, vol.362, pp.782-790, 2003.

E. Braunwald, M. J. Domanski, S. E. Fowler, N. L. Geller, B. J. Gersh et al.,

, Angiotensin-converting-enzyme inhibition in stable coronary artery disease

J. Engl and . Med, , vol.351, pp.2058-68, 2004.

P. Even and B. Debré, Guide des 4000 médicaments utiles, inutiles ou dangereux. Le cherche midi, 2012.

P. G. Steg, One-year cardiovascular event rates in outpatients with atherothrombosis, JAMA, vol.297, pp.1197-206, 2007.

G. W. Stone, A prospective natural-history study of coronary atherosclerosis, N Engl J Med, vol.364, issue.3, p.38, 2011.

A. Astier, F. Blanchet, A. Brouard, P. Y. Chambrin, and J. L. Delmas, Rapport de l'académie de pharmacie. Observance des traitements médicamenteux en France, 2015.

M. M. Fulton and E. R. Et-allen, Polypharmacy in the elderly: a literature review, J Am Acad.Nurse ? Pract, vol.17, issue.4, pp.123-132, 2005.

E. R. Hajjar, A. C. Cafiero, and J. T. Et-hanlon, Polypharmacy in elderly patients, Am J Geriatr. Pharmacother, vol.5, issue.4, pp.345-351, 2007.

M. Monégat, C. Sermet, and M. Perronnin, «La polymédication : définitions, mesures et enjeux Revue de la littérature et tests de mesure», 2014.

A. Aouba, M. Eb, G. Rey, G. Pavillon, and E. Jougla, Données sur la mortalité en France : principales causes de décès en 2008 et évolutions depuis, Bull Epidémiol Hebd, issue.22, pp.249-55, 2000.

C. Droz, C. Dureau, D. Thomas, N. Danchin, J. Tricoire et al., , vol.17, p.476, 2014.

P. Tuppin, A. Neumann, N. Danchin, A. Weill, P. Ricordeau et al.,

, Chaînage des données du PMSI avec les données de remboursement de l'assurance-maladie : exemple de l'analyse de la prévention secondaire après un infarctus du myocarde. Rev DÉpidémiologie Santé Publique, vol.57, p.87, 2009.

, Actes et prestations. Affections de longue durée. HAS, 2016.